Does the FDA say HRT helps heart health

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

The FDA does not say that HRT helps with cardiovascular outcomes or prevents heart disease. According to FDA.gov, menopausal hormone therapy is approved only for relief of vasomotor symptoms such as hot flashes and night sweats, for vaginal atrophy symptoms, and for bone protection in certain postmenopausal women. According to the FDA-approved prescribing information for systemic estrogens, these products carry boxed warnings stating that hormone therapy should not be used to prevent heart disease or other cardiovascular conditions.

What the FDA Actually Says About HRT and the Heart

According to FDA Drug Safety Communication and the FDA-approved prescribing information for systemic estrogens, the FDA's position is based on large clinical studies showing that hormone therapy is not a cardioprotective treatment. Prior to these studies, many believed estrogen might reduce cardiovascular risk. According to the WHI, research showed that starting HRT later in life may increase risks such as blood clots, stroke, and pulmonary embolism. Because of this evidence, the FDA requires boxed warning labeling on systemic estrogen products stating that HRT must not be used for cardiovascular disease prevention. Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

Why the FDA Takes This Stance

• Evidence does not show cardiovascular protection: According to the WHI, women who started HRT many years after menopause did not have fewer cardiovascular events in major trials.
• Timing matters: According to NAMS, some research suggests that women who start HRT near the time of menopause may not have increased cardiovascular risks, and some may have neutral outcomes. However, according to FDA.gov, this evidence is not sufficient for the FDA to approve HRT as a cardiovascular treatment.
• Risk varies by type and route: According to the FDA-approved prescribing information for systemic estrogens, estrogen alone, estrogen with progestogen, and transdermal versus oral forms may behave differently in the body. Because the patterns are complex, the FDA maintains conservative labeling guidance across all forms.

What This Means for You

Using HRT for symptom relief may be appropriate when it matches your health profile, as determined by a qualified prescriber. Many postmenopausal women in their 40s and 50s use commercially available hormone therapy under medical supervision. However, it is important to understand that, according to FDA.gov, the FDA does not recommend HRT for preventing cardiovascular disease. Cardiovascular risk reduction still relies on established approaches: blood pressure management, cholesterol monitoring, physical activity, nutrition, and stress management.

If you are considering HRT and wondering how it fits with your personal cardiovascular risk profile, that is a decision to make openly with a qualified prescriber. Many women may still use commercially available hormone therapy with the right form, dose, and timing under appropriate medical oversight.

Important note: According to the FDA-approved prescribing information for systemic estrogens, these products carry boxed warnings regarding increased risk of stroke, deep vein thrombosis, and pulmonary embolism. Hormone therapy is NOT indicated for cardiovascular disease prevention. Clinical decisions about hormone therapy and cardiovascular risk should be made with a qualified prescriber.